Olivier S Descamps
Overview
Explore the profile of Olivier S Descamps including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
3814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Langlois M, Nordestgaard B, Langsted A, Chapman M, Aakre K, Baum H, et al.
Clin Chem Lab Med
. 2019 Dec;
58(4):496-517.
PMID: 31855562
The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory...
12.
Descamps O, Verhaegen A, Demeure F, Langlois M, Rietzschel E, Mertens A, et al.
Acta Clin Belg
. 2019 Dec;
75(1):80-90.
PMID: 31846601
It has been well established that low-density lipoproteins (LDL) and other apolipoprotein B-containing lipoproteins are causally related to atherosclerotic cardiovascular disease (ASCVD) and that lowering these lipoproteins reduces the risk...
13.
Ramaswami U, Futema M, Bogsrud M, Holven K, Roeters van Lennep J, Wiegman A, et al.
Atherosclerosis
. 2019 Dec;
292:178-187.
PMID: 31809987
Background And Aims: For children with heterozygous familial hypercholesterolaemia (HeFH), European guidelines recommend consideration of statin therapy by age 8-10 years for those with a low density lipoprotein cholesterol (LDL-C)...
14.
Banach M, Bruckert E, Descamps O, Ellegard L, Ezhov M, Foger B, et al.
Atheroscler Suppl
. 2019 Aug;
39:e1-e8.
PMID: 31451336
No abstract available.
15.
Descamps O, Van Caenegem O, Hermans M, Balligand J, Beauloye C, Bondue A, et al.
Atherosclerosis
. 2018 Oct;
277:369-376.
PMID: 30270073
Background And Aims: Familial hypercholesterolaemia (FH) is an autosomal dominant lipoprotein disorder characterized by significant elevation of low-density lipoprotein cholesterol (LDL-C) and markedly increased risk of premature cardiovascular disease (CVD)....
16.
Langlois M, Chapman M, Cobbaert C, Mora S, Remaley A, Ros E, et al.
Clin Chem
. 2018 May;
64(7):1006-1033.
PMID: 29760220
Background: The European Atherosclerosis Society-European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to optimize atherogenic lipoprotein quantification for cardiovascular risk management. Content: We critically...
17.
Descamps O, Fraass U, Dent R, Marz W, Gouni-Berthold I
Int J Clin Pract
. 2017 Jul;
71(8).
PMID: 28750477
Objectives: To put data from our recent systematic review of phase 3 studies of anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies into the context of clinical practice. Methods: Data from...
18.
Gouni-Berthold I, Descamps O, Fraass U, Hartfield E, Allcott K, Dent R, et al.
Br J Clin Pharmacol
. 2016 Aug;
82(6):1412-1443.
PMID: 27478094
Aims: Two anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, have been approved for the treatment of hypercholesterolaemia in certain patients. We reviewed data from Phase 3...
19.
Cuchel M, Bruckert E, Ginsberg H, Raal F, Santos R, Hegele R, et al.
Turk Kardiyol Dern Ars
. 2016 Jun;
43 Suppl 1:1-14.
PMID: 27326442
No abstract available.
20.
Nordestgaard B, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al.
Clin Chem
. 2016 May;
62(7):930-46.
PMID: 27235445
Aims: To critically evaluate the clinical implications of the use of non-fasting rather than fasting lipid profiles and to provide guidance for the laboratory reporting of abnormal non-fasting or fasting...